Lindbrook Capital LLC Purchases 268 Shares of DexCom, Inc. (NASDAQ:DXCM)

Lindbrook Capital LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 20.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,583 shares of the medical device company’s stock after purchasing an additional 268 shares during the period. Lindbrook Capital LLC’s holdings in DexCom were worth $196,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of DXCM. SG Americas Securities LLC raised its holdings in DexCom by 20.6% in the 3rd quarter. SG Americas Securities LLC now owns 47,447 shares of the medical device company’s stock valued at $4,427,000 after buying an additional 8,100 shares during the last quarter. Founders Financial Securities LLC lifted its holdings in shares of DexCom by 7.6% during the third quarter. Founders Financial Securities LLC now owns 3,483 shares of the medical device company’s stock worth $325,000 after purchasing an additional 246 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of DexCom by 2.3% in the third quarter. Exchange Traded Concepts LLC now owns 13,338 shares of the medical device company’s stock worth $1,244,000 after purchasing an additional 306 shares during the last quarter. LaFleur & Godfrey LLC increased its holdings in DexCom by 185.4% in the third quarter. LaFleur & Godfrey LLC now owns 4,566 shares of the medical device company’s stock valued at $426,000 after purchasing an additional 2,966 shares during the period. Finally, Caprock Group LLC increased its holdings in DexCom by 2.8% in the third quarter. Caprock Group LLC now owns 17,611 shares of the medical device company’s stock valued at $1,643,000 after purchasing an additional 480 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $137.81, for a total value of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock worth $25,530,859 in the last quarter. Insiders own 0.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on DXCM shares. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. StockNews.com upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Finally, UBS Group lifted their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $141.40.

DexCom Trading Up 0.6 %

NASDAQ DXCM opened at $131.52 on Tuesday. DexCom, Inc. has a 52 week low of $74.75 and a 52 week high of $142.00. The business has a 50 day moving average price of $129.81 and a 200-day moving average price of $117.38. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. The company has a market cap of $50.70 billion, a price-to-earnings ratio of 100.40, a P/E/G ratio of 2.25 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom’s quarterly revenue was up 26.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 EPS. As a group, equities analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.